{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:35:57Z","timestamp":1784691357697,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011852","name":"Paracelsus Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011852","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>In ultrahypofractionated radiation concepts, managing of intrafractional motion is mandatory because tighter margins are used and random errors resulting from prostate movement are not averaged out over a\u00a0large number of fractions. Noninvasive live monitoring of prostate movement is a\u00a0desirable asset for LINAC-based prostate stereotactic body radiation therapy (SBRT).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We prospectively analyzed a\u00a0novel live tracking device (RayPilot HypoCath\u2122; Micropos Medical AB, Gothenburg, Sweden) where a\u00a0transmitter is noninvasively positioned in the prostatic urethra using a\u00a0Foley catheter in 12\u00a0patients undergoing ultrahypofractionated intensity-modulated radiation therapy (IMRT) of the prostate. Gold fiducials (Innovative Technology V\u00f6lp, Innsbruck, Austria) were implanted to allow comparison of accuracy and positional stability of the HypoCath system and its ability to be used as a\u00a0standalone IGRT method. Spatial stability of the transponder was assessed by analyzing transmitter movement in relation to gold markers (GM) in superimposed kV image pairs. Inter- and intrafractional prostate movement and the impact of its correction were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 64\u00a0fractions were analyzed. The average resulting deviation vector compared to the GM-based position was 1.2\u202fmm and 0.7\u202fmm for inter- and intrafractional motion, respectively. The mean intrafractional displacement vector of the prostate was 1.9\u202fmm. Table readjustment due to exceeding the threshold of 3\u202fmm was required in 18.8% of fractions. Repositioning reduced the time spent outside the 3\u2011mm margin from 7.9% to 3.8% of beam-on time. However, for individual patients, the time spent outside the 3\u2011mm margin was reduced from to 49% to 19%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>the HypoCath system allows highly accurate and robust intrafractional motion monitoring. In conjunction with cone beam CT (CBCT) for initial patient setup, it could be used as a\u00a0standalone image-guided radiation therapy (IGRT) system.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00066-023-02125-2","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T18:02:25Z","timestamp":1692986545000},"page":"195-201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Noninvasive inter- and intrafractional motion control in ultrahypofractionated radiation therapy of prostate cancer using RayPilot HypoCath\u2122\u2014a\u00a0substitute for gold fiducial-based IGRT?"],"prefix":"10.1007","volume":"200","author":[{"given":"Johannes","family":"Berchtold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Karner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Groher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Gaisberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Sedlmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2835-3049","authenticated-orcid":false,"given":"Frank","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"issue":"10162","key":"2125_CR1","doi-asserted-by":"publisher","first-page":"32486","DOI":"10.1016\/s0140-6736","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker\u00a0CC, James\u00a0ND, Brawley\u00a0CD, Clarke\u00a0NW, Hoyle\u00a0AP, Ali\u00a0A, Ritchie\u00a0AWS, Attard\u00a0G, Chowdhury\u00a0S, Cross\u00a0W, Dearnaley\u00a0DP, Gillessen\u00a0S, Gilson\u00a0C, Jones\u00a0RJ, Langley\u00a0RE, Malik\u00a0ZI, Mason\u00a0MD, Matheson\u00a0D, Millman\u00a0R, Russell\u00a0JM, Thalmann\u00a0GN, Amos\u00a0CL, Alonzi\u00a0R, Bahl\u00a0A, Birtle\u00a0A, Din\u00a0O, Douis\u00a0H, Eswar\u00a0C, Gale\u00a0J, Gannon\u00a0MR, Jonnada\u00a0S, Khaksar\u00a0S, Lester\u00a0JF, O\u2019Sullivan\u00a0JM, Parikh\u00a0OA, Pedley\u00a0ID, Pudney\u00a0DM, Sheehan\u00a0DJ, Srihari\u00a0NN, Tran\u00a0ATH, Parmar\u00a0MKB, Sydes\u00a0MR (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a\u00a0randomised controlled phase 3\u00a0trial. Lancet 392(10162):32486\u201332483. https:\/\/doi.org\/10.1016\/s0140-6736","journal-title":"Lancet"},{"issue":"3","key":"2125_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"LMS Boeve","year":"2019","unstructured":"Boeve\u00a0LMS, Hulshof\u00a0M, Vis\u00a0AN, Zwinderman\u00a0AH, Twisk\u00a0JWR, Witjes\u00a0WPJ, Delaere\u00a0KPJ, Moorselaar\u00a0R, Verhagen\u00a0P, van Andel\u00a0G (2019) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a\u00a0prospective randomised clinical trial: Data from the HORRAD trial. Eur Urol 75(3):410\u2013418. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.008","journal-title":"Eur Urol"},{"issue":"10196","key":"2125_CR3","doi-asserted-by":"publisher","first-page":"31131","DOI":"10.1016\/s0140-6736","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark\u00a0A, Gunnlaugsson\u00a0A, Beckman\u00a0L, Thellenberg-Karlsson\u00a0C, Hoyer\u00a0M, Lagerlund\u00a0M, Kindblom\u00a0J, Ginman\u00a0C, Johansson\u00a0B, Bjornlinger\u00a0K, Seke\u00a0M, Agrup\u00a0M, Fransson\u00a0P, Tavelin\u00a0B, Norman\u00a0D, Zackrisson\u00a0B, Anderson\u00a0H, Kjellen\u00a0E, Franzen\u00a0L, Nilsson\u00a0P (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5\u2011year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3\u00a0trial. Lancet 394(10196):31131\u201331136. https:\/\/doi.org\/10.1016\/s0140-6736","journal-title":"Lancet"},{"issue":"11","key":"2125_CR4","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/s1470-2045(19)30569-8","volume":"20","author":"DH Brand","year":"2019","unstructured":"Brand\u00a0DH, Tree\u00a0AC, Ostler\u00a0P, van der Voet\u00a0H, Loblaw\u00a0A, Chu\u00a0W, Ford\u00a0D, Tolan\u00a0S, Jain\u00a0S, Martin\u00a0A, Staffurth\u00a0J, Camilleri\u00a0P, Kancherla\u00a0K, Frew\u00a0J, Chan\u00a0A, Dayes\u00a0IS, Henderson\u00a0D, Brown\u00a0S, Cruickshank\u00a0C, Burnett\u00a0S, Duffton\u00a0A, Griffin\u00a0C, Hinder\u00a0V, Morrison\u00a0K, Naismith\u00a0O, Hall\u00a0E, van As\u00a0N (2019) Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 20(11):1531\u20131543. https:\/\/doi.org\/10.1016\/s1470-2045(19)30569-8","journal-title":"Lancet Oncol"},{"issue":"4","key":"2125_CR5","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","volume":"104","author":"WC Jackson","year":"2019","unstructured":"Jackson\u00a0WC, Silva\u00a0J, Hartman\u00a0HE, Dess\u00a0RT, Kishan\u00a0AU, Beeler\u00a0WH, Gharzai\u00a0LA, Jaworski\u00a0EM, Mehra\u00a0R, Hearn\u00a0JWD, Morgan\u00a0TM, Salami\u00a0SS, Cooperberg\u00a0MR, Mahal\u00a0BA, Soni\u00a0PD, Kaffenberger\u00a0S, Nguyen\u00a0PL, Desai\u00a0N, Feng\u00a0FY, Zumsteg\u00a0ZS, Spratt\u00a0DE (2019) Stereotactic body radiation therapy for localized prostate cancer: A systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys 104(4):778\u2013789. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.03.051","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2125_CR6","unstructured":"(2022) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Prostate Cancer, Version 4.2022\u2014May 10, 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed 12.\u00a0June 2022"},{"issue":"2","key":"2125_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00066-020-01723-8","volume":"197","author":"F Wolf","year":"2021","unstructured":"Wolf\u00a0F, Sedlmayer\u00a0F, Aebersold\u00a0D, Albrecht\u00a0C, B\u00f6hmer\u00a0D, Flentje\u00a0M, Ganswindt\u00a0U, Ghadjar\u00a0P, H\u00f6cht\u00a0S, H\u00f6lscher\u00a0T, M\u00fcller\u00a0AC, Niehoff\u00a0P, Pinkawa\u00a0M, Schmidt-Hegemann\u00a0NS, Zamboglou\u00a0C, Zips\u00a0D, Wiegel\u00a0T (2021) Ultrahypofractionation of localized prostate cancer: Statement from the DEGRO working group prostate cancer. Strahlenther Onkol 197(2):89\u201396. https:\/\/doi.org\/10.1007\/s00066-020-01723-8","journal-title":"Strahlenther Onkol"},{"issue":"4","key":"2125_CR8","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.ijrobp.2007.11.054","volume":"71","author":"KM Langen","year":"2008","unstructured":"Langen\u00a0KM, Willoughby\u00a0TR, Meeks\u00a0SL, Santhanam\u00a0A, Cunningham\u00a0A, Levine\u00a0L, Kupelian\u00a0PA (2008) Observations on real-time prostate gland motion using electromagnetic tracking. Int J Radiat Oncol Biol Phys 71(4):1084\u20131090. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.11.054","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2125_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.radonc.2018.05.031","volume":"128","author":"K Braide","year":"2018","unstructured":"Braide\u00a0K, Lindencrona\u00a0U, Welinder\u00a0K, G\u00f6tstedt\u00a0J, St\u00e5hl\u00a0I, Pettersson\u00a0N, Kindblom\u00a0J (2018) Clinical feasibility and positional stability of an implanted wired transmitter in a\u00a0novel electromagnetic positioning system for prostate cancer radiotherapy. Radiother Oncol 128(2):336\u2013342. https:\/\/doi.org\/10.1016\/j.radonc.2018.05.031","journal-title":"Radiother Oncol"},{"issue":"3","key":"2125_CR10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.radonc.2008.08.018","volume":"90","author":"J Kindblom","year":"2009","unstructured":"Kindblom\u00a0J, Ekelund-Olvenmark\u00a0AM, Syren\u00a0H, Iustin\u00a0R, Braide\u00a0K, Frank-Lissbrant\u00a0I, Lennern\u00e4s\u00a0B (2009) High precision transponder localization using a\u00a0novel electromagnetic positioning system in patients with localized prostate cancer. Radiother Oncol 90(3):307\u2013311. https:\/\/doi.org\/10.1016\/j.radonc.2008.08.018","journal-title":"Radiother Oncol"},{"key":"2125_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.radonc.2020.12.013","volume":"156","author":"M Jaccard","year":"2021","unstructured":"Jaccard\u00a0M, Ehrbar\u00a0S, Miralbell\u00a0R, Hagen\u00a0T, Koutsouvelis\u00a0N, Poulsen\u00a0P, Rouzaud\u00a0M, Tanadini-Lang\u00a0S, Tsoutsou\u00a0P, Guckenberger\u00a0M, Zilli\u00a0T (2021) Single-fraction prostate stereotactic body radiotherapy: Dose reconstruction with electromagnetic intrafraction motion tracking. Radiother Oncol 156:145\u2013152. https:\/\/doi.org\/10.1016\/j.radonc.2020.12.013","journal-title":"Radiother Oncol"},{"issue":"2","key":"2125_CR12","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ijrobp.2006.01.050","volume":"65","author":"TR Willoughby","year":"2006","unstructured":"Willoughby\u00a0TR, Kupelian\u00a0PA, Pouliot\u00a0J, Shinohara\u00a0K, Aubin\u00a0M, Roach\u00a0M 3rd, Skrumeda\u00a0LL, Balter\u00a0JM, Litzenberg\u00a0DW, Hadley\u00a0SW, Wei\u00a0JT, Sandler\u00a0HM (2006) Target localization and real-time tracking using the Calypso 4D localization system in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 65(2):528\u2013534. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.01.050","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2125_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1186\/s13014-019-1248-6","volume":"14","author":"A Schorghofer","year":"2019","unstructured":"Schorghofer\u00a0A, Drerup\u00a0M, Kunit\u00a0T, Lusuardi\u00a0L, Holzinger\u00a0J, Karner\u00a0J, Groher\u00a0M, Zoubek\u00a0C, Forstner\u00a0R, Sedlmayer\u00a0F, Wolf\u00a0F (2019) Rectum-spacer related acute toxicity\u2014endoscopy results of 403 prostate cancer patients after implantation of gel or balloon spacers. Radiat Oncol 14(1):403\u2013447. https:\/\/doi.org\/10.1186\/s13014-019-1248-6","journal-title":"Radiat Oncol"},{"key":"2125_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.07.027","author":"F Wolf","year":"2015","unstructured":"Wolf\u00a0F, Gaisberger\u00a0C, Ziegler\u00a0I, Krenn\u00a0E, Scherer\u00a0P, Hruby\u00a0S, Schatz\u00a0T, Forstner\u00a0R, Holzinger\u00a0J, Vaszi\u00a0A, Kametriser\u00a0G, Steininger\u00a0P, Deutschmann\u00a0H, Sedlmayer\u00a0F (2015) Comparison of two different rectal spacers in prostate cancer external beam radiotherapy in terms of rectal sparing and volume consistency. Radiother Oncol. https:\/\/doi.org\/10.1016\/j.radonc.2015.07.027","journal-title":"Radiother Oncol"},{"issue":"4","key":"2125_CR15","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S0360-3016(00)00518-6","volume":"47","author":"M van Herk","year":"2000","unstructured":"van Herk\u00a0M, Remeijer\u00a0P, Rasch\u00a0C, Lebesque\u00a0JV (2000) The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy. Int J Radiat Oncol Biol Phys 47(4):1121\u20131135","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2125_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.semradonc.2003.10.003","volume":"14","author":"M van Herk","year":"2004","unstructured":"van Herk\u00a0M (2004) Errors and margins in radiotherapy. Semin Radiat Oncol 14(1):52\u201364. https:\/\/doi.org\/10.1053\/j.semradonc.2003.10.003","journal-title":"Semin Radiat Oncol"},{"issue":"7","key":"2125_CR17","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/jco.20.02873","volume":"39","author":"LGW Kerkmeijer","year":"2021","unstructured":"Kerkmeijer\u00a0LGW, Groen\u00a0VH, Pos\u00a0FJ, Haustermans\u00a0K, Monninkhof\u00a0EM, Smeenk\u00a0RJ, Kunze-Busch\u00a0M, de Boer\u00a0JCJ, van der Voort van Zijp\u00a0J, van Vulpen\u00a0M, Draulans\u00a0C, van den Bergh\u00a0L, Isebaert\u00a0S, van der Heide\u00a0UA (2021) Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: Results from the FLAME randomized phase\u00a0III trial. J\u00a0Clin Oncol 39(7):787\u2013796. https:\/\/doi.org\/10.1200\/jco.20.02873","journal-title":"J Clin Oncol"},{"key":"2125_CR18","doi-asserted-by":"publisher","first-page":"883725","DOI":"10.3389\/fonc.2022.883725","volume":"12","author":"D Panizza","year":"2022","unstructured":"Panizza\u00a0D, Faccenda\u00a0V, Lucchini\u00a0R, Daniotti\u00a0MC, Trivellato\u00a0S, Caricato\u00a0P, Pisoni\u00a0V, De Ponti\u00a0E, Arcangeli\u00a0S (2022) Intrafraction prostate motion management during dose-escalated linac-based stereotactic body radiation therapy. Front Oncol 12:883725. https:\/\/doi.org\/10.3389\/fonc.2022.883725","journal-title":"Front Oncol"},{"issue":"3","key":"2125_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","volume":"9","author":"AU Kishan","year":"2023","unstructured":"Kishan\u00a0AU, Ma\u00a0TM, Lamb\u00a0JM, Casado\u00a0M, Wilhalme\u00a0H, Low\u00a0DA, Sheng\u00a0K, Sharma\u00a0S, Nickols\u00a0NG, Pham\u00a0J, Yang\u00a0Y, Gao\u00a0Y, Neylon\u00a0J, Basehart\u00a0V, Cao\u00a0M, Steinberg\u00a0ML (2023) Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: The MIRAGE randomized clinical trial. JAMA 9(3):365\u2013373. https:\/\/doi.org\/10.1001\/jamaoncol.2022.6558","journal-title":"JAMA"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02125-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-023-02125-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02125-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T16:03:22Z","timestamp":1708358602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-023-02125-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2125"],"URL":"https:\/\/doi.org\/10.1007\/s00066-023-02125-2","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]},"assertion":[{"value":"18 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.\u00a0Berchtold, C.\u00a0Winkler, J.\u00a0Karner, M.\u00a0Groher, C.\u00a0Gaisberger, F.\u00a0Sedlmayer and F.\u00a0Wolf declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and\/or national research committee (<i>Ethikkommission d. Landes Salzburg, <\/i>vote no.:\u00a01168\/2021) and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}